1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BioNTech SE

BioNTech SE

22UA.F
BioNTech SEundefined flagFrankfurt Stock Exchange
81.20
EUR
-2.25
- -
20.53BMarket Cap
BioNTech SE
22UA.F
(Frankfurt Stock Exchange)

Recent

price

81.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.27
0.56
0.51
1.9
77.77
71.16
15.87
11.45
11.87
11.47
Revenue per Share
- -
-0.38
-0.21
-0.85
0.06
42.18
38.78
3.87
-2.77
-4.7
-5.12
Basic EPS, GAAP
- -
-0.49
-0.56
-1.27
-0.39
3.02
54.32
19.39
-1.02
-1.21
2.48
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
1.99
- -
- -
- -
- -
Dividend per Share
- -
-0.14
-0.23
-0.91
-0.64
41.51
78.43
83.17
80.55
75.38
72.34
Book Value per Share
- -
-0.58
0.79
1.91
4.77
47.92
81.54
79.3
75.94
71.36
68.63
Tangible Book Value per Share
- -
227
227
212
253
244
243
241
240
242
245
Basic Weighted Avg Shares
- -
62
128
109
482
18,977
17,311
3,819
2,751
2,870
2,805
Sales/Revenue/Turnover
- -
-99.48
-42.25
-167.13
-17.08
78.66
71.08
22.93
-25.79
-22.32
-27.67
Operating Margin (%)
- -
11
22
34
39
75
123
183
298
383
461
Depreciation Expense
- -
-86
-48
-179
15
10,292
9,434
930
-665
-1,136
-1,252
Net Income, GAAP
- -
- -
- -
- -
- -
31.59
27.17
21.57
- -
- -
216.19
Effective Tax Rate (%)
- -
-139.05
-37.64
-164.92
3.15
54.24
54.5
24.36
-24.18
-39.59
-44.64
Profit Margin (%)
261
31
323
422
1,061
11,591
18,971
17,457
16,280
14,004
13,767
Working Capital
27
50
54
69
231
172
176
191
215
215
246
LT Debt
32
-48
267
493
1,372
11,894
20,056
20,246
19,411
19,224
18,698
Total Equity
- -
- -
- -
- -
- -
132.82
51.75
3.28
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
195.98
63.57
4.74
- -
- -
-2.85
Return on Capital (%)
- -
- -
- -
- -
- -
- -
64.6
4.76
-3.38
-6.05
-6.84
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
53
52
57
LT Borrowings
192
215
67
LT Finance Leases
- -
- -
180
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
240
251
253
Market Capitalization
19,973
19,629
18,559

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
15,831
16,147
15,532
Cash, Cash Equivalents & STI
14,519
14,877
14,639
Accounts Receivable, Net
691
924
539
Inventories
226
111
104
Total Current Liabilities
2,222
2,142
1,765
Payables & Accruals
406
600
507
ST Debt
53
52
57
Deferred Revenue
796
755
758

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
166.3%
-0.96%
Free Cash Flow
- -
140.42%
19.79%
Net Income, GAAP
- -
13,482.92%
70.77%
Sales/Revenue/Turnover
- -
744.85%
4.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
188
129
1,245
1,190
2,751
2025
183
261
1,519
907
2,870
2026
118
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.31
-3.36
0.82
1.08
-2.77
2025
-1.73
-1.6
-0.12
-1.25
-4.7
2026
-2.1
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
MBX Biosciences, Inc. Common Stock (MBX)
AnPac Bio-Medical Science Co., Ltd. (ANPC)
NightHawk Biosciences, Inc. (NHWK)
Yulong Eco-Materials Limited (YECO)
Anavex Life Sciences Corp. (0HFR.L)
Acasti Pharma Inc. (ACST)
Business
BioNTech SE operates as a biotechnology entity, concentrating on the advancement and commercialization of pioneering immunotherapies designed to combat cancer and various infectious ailments. The company is actively progressing its FixVac platform product candidates, including BNT111, an mRNA-based therapy undergoing Phase 2 clinical assessment for advanced melanoma; BNT112, in Phase 1/2a clinical investigation for prostate cancer; and BNT113, which is in Phase 2/3 clinical evaluation for human papillomavirus 16 positive head and neck cancers. Further, BNT116, an mRNA vaccine targeting non-small cell lung cancer, has initiated global clinical trials. Its diverse oncology portfolio extends to neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), currently in Phase 2 clinical trials for melanoma. Additionally, BioNTech develops intratumoral mRNA immunotherapies, including BNT141 and BNT142, in Phase 1 studies for multiple solid tumors, and RiboCytokines like BNT151, BNT152, and BNT153 for various solid tumor indications. The company is also advancing chimeric antigen receptor T cell immunotherapies, notably BNT211, targeting CLDN6-positive solid tumors in Phase 1/2 trials, and checkpoint immunomodulators such as GEN1046 and GEN1042, which are in Phase 1/2 clinical assessment for solid tumors. A significant bispecific antibody candidate, BNT327/PM8002, is progressing into global Phase 2/3 clinical trials for conditions like non-small cell lung cancer, triple-negative breast cancer, and pancreatic cancer. Beyond oncology, BioNTech is renowned for its contributions to infectious disease prevention, co-developing the widely recognized COVID-19 vaccine, Comirnaty, with Pfizer Inc. Its infectious disease pipeline encompasses mRNA-based vaccine candidates for influenza, shingles, malaria, tuberculosis, HIV, and mpox. The company also explores therapies for rare diseases. BioNTech leverages advanced technological platforms, including its proprietary mRNA technology, and has integrated artificial intelligence and machine learning into its drug discovery processes through collaborations like the AI Innovation Lab with InstaDeep. BioNTech maintains extensive strategic alliances with various global pharmaceutical partners, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Regeneron Pharmaceuticals, Inc., Bristol Myers Squibb, and Ryvu Therapeutics. The company was established in 2008 and is based in Mainz, Germany.